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AbstrAct
Background In a phase II North American study 
(NP28761; NCT01871805), the anaplastic lymphoma 
kinase (ALK) inhibitor alectinib demonstrated both 
systemic and central nervous system (CNS) efficacy with 
good tolerability in patients with ALK-positive non-small 
cell lung cancer. We describe patient-reported outcomes 
(PROs) from the NP28761 study.
Patients and methods PROs and health-related quality 
of life (HRQoL) benefits were assessed using two self-
administered questionnaires (the European Organisation 
for Research and Treatment of Cancer 30-Item Quality 
of Life Questionnaire-Core (EORTC QLQ-C30), and the 
13-item EORTC QLQ-lung cancer-specific module) at 
enrolment and every 6 weeks until week 66, disease 
progression or death.
Results Clinically meaningful mean improvements 
(≥10 point change from baseline) were observed in 10 
domains, including global health status (GHS), role and 
social functioning, fatigue, pain, dyspnoea, and appetite 
loss. A clinically meaningful improvement was observed 
in GHS from the first assessment (6 weeks) until week 60. 
Alectinib demonstrated a rapid effect, with a median time 
to symptom improvement, using the composite endpoint 
of cough, dyspnoea and pain in the chest, of 1.4 months 
(6.1 weeks) (95% CI 1.4 to 1.6) and a median time to 
symptom deterioration of 5.1 months (22.1 weeks) (95% CI 
2.8 to 6.8). Patients with CNS metastases at baseline 
experienced comparable HRQoL over the duration of the 
study as patients without CNS metastases. Exploratory 
analysis showed that the occurrence of an objective 
response may be associated with a better HRQoL.
Conclusions Patients treated with alectinib in this phase 
II study achieved clinically meaningful improvements in 
HRQoL and symptoms and had delayed time to symptom 
deterioration.
IntRoduCtIon
Non-small cell lung cancer (NSCLC) is 
the most common subtype of lung cancer, 
accounting for around 80%–85% of all cases. 
In the majority of patients, the disease has 
reached an advanced stage by the time of 
diagnosis1 and often results in substantial 
symptom burden (eg, fatigue, dyspnoea, 
cough and pain).2 While more conventional 
anticancer therapies, such as chemotherapy, 
provide a marginal improvement in overall 
survival, the side effects are often signifi-
cant, which may overshadow the treatment 
Key questions
What is already known about this subject?
 ► Alectinib has shown promising systemic and central 
nervous system (CNS) efficacy in the treatment of 
patients with anaplastic lymphoma kinase-positive 
(ALK+) non-small cell lung cancer (NSCLC) who 
were previously treated with crizotinib, and is well 
tolerated.
 ► Additionally, alectinib has now demonstrated sig-
nificantly superior efficacy compared with crizotinib 
in patients with advanced treatment-naïve ALK+ 
NSCLC.
What does this study add?
 ► This current analysis is the first to demonstrate that 
alectinib can both improve patient-reported symp-
tom burden and enhance health-related quality of 
life (HRQoL).
 ► The median time to patient-reported outcome (PRO) 
symptom improvement with alectinib was 1.4 
months (95% CI 1.4 to 1.6).
 ► Baseline CNS metastases did not impact HRQoL 
over the duration of the study.
How might this impact on clinical practice?
 ► Patients treated with alectinib in the North American 
NP28761 study reported clinically meaningful 
improvement in key lung cancer symptoms, pa-
tient-reported function and HRQoL while remaining 
a tolerable treatment option.
 ► These PRO data are consistent with the safety data 
previously reported and confirm the tolerability of 
alectinib in patients with ALK+ NSCLC who were 
previously treated with crizotinib.
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benefits. This can be detrimental to a patient’s health-re-
lated quality of life (HRQoL), impacting physical, 
emotional and social functioning. Hence, many clinical 
trials now include patients’ self-ratings on the impact of 
disease treatment on symptoms, functioning and HRQoL 
(collectively referred to as patient-reported outcomes 
(PRO)) as study endpoints to inform the assessment of 
clinical benefit.
Anaplastic lymphoma kinase-positive NSCLC (ALK-pos-
itive NSCLC) is a distinct subset of lung cancer which is 
characterised by rearrangements of the ALK gene. The 
current standard of care for ALK-positive NSCLC is the 
ALK tyrosine kinase inhibitor (TKI) crizotinib, which 
has demonstrated improved response rates and HRQoL 
compared with chemotherapy.3 4 However, progression 
usually occurs within 1 year of treatment on crizotinib, 
with the most common site of progression being the 
central nervous system (CNS).
Alectinib is an oral ALK TKI which has demonstrated 
efficacy for patients with ALK-positive NSCLC, both 
systemically and in the CNS.5–9 In the single-arm, phase II, 
North American study of alectinib in ALK-positive NSCLC 
in patients who were previously treated with crizotinib 
(NP28761; NCT01871805), at the April 2015 data cut-off, 
an objective response rate (ORR) of 52.2% (n=35/67) 
was reported in patients with measurable disease at base-
line according to the independent review committee 
(IRC), with a median progression-free survival of 8.1 
months (95% CI 6.2 to 12.6) and a median duration of 
response (DOR) of 13.5 months (95% CI 6.7 to not esti-
mable). In patients with measurable CNS metastases at 
baseline, alectinib demonstrated a CNS ORR of 75.0% 
(95% CI 47.6 to 92.7) and a CNS DOR of 11.1 months 
(95% CI 5.8 to 11.1). Here, we summarise the PRO data 
from this study.
PatIents and metHods
study design and patients
The design of the NP28761 study has been published 
previously.7 Briefly, this was a single-arm, multicentre 
study. Eligible patients were aged ≥18 years, with locally 
advanced or metastatic (stage IIIB–IV) ALK-positive 
NSCLC, which was confirmed by a US Food and Drug 
Administration-approved fluorescent in situ hybridisa-
tion test, and an Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0–2. Patients had 
progressed on crizotinib. Baseline CNS metastases were 
permitted, providing they were asymptomatic.
Patients received 600 mg of oral alectinib twice daily. 
The primary endpoint of the study was ORR according to 
the Response Evaluation Criteria in Solid Tumours V.1.1 
as assessed by an IRC. HRQoL, as measured by the global 
health status (GHS) scale of the European Organisation 
for Research and Treatment of Cancer 30-Item Quality 
of Life Questionnaire-Core (EORTC QLQ-C30), was 
defined as the secondary endpoint.
The study was undertaken in accordance with the 
principles of the Declaration of Helsinki, and written 
informed consent was obtained from all patients.
Patient-completed questionnaires
Patient-reported symptoms and HRQoL were assessed 
using two self-administered questionnaires that have been 
routinely used to describe PROs in lung cancer studies.4 10 
The first questionnaire is the EORTC QLQ-C30,11 which 
comprises 30 questions across five functional scales 
(physical, role, social, cognitive and emotional), a GHS 
scale, three symptom scales (fatigue, pain and nausea/
vomiting) and various single-item symptom scales. The 
second questionnaire is the EORTC QLQ-lung cancer-spe-
cific module (EORTC QLQ-LC13),12 which comprises 
13 questions assessing lung cancer-specific symptoms, 
including cough, dyspnoea, pain in the chest and others. 
Data were collected at randomisation and every 6 weeks 
until week 66, disease progression or death.
statistical analyses
Questionnaire items were scored according to the EORTC 
algorithms,13 which standardise the raw score to a range 
of 0–100. For the functional scales and GHS items, a 
higher score represents a better level of functioning. For 
each of the symptom scales, a lower score represents a 
lower level of that particular symptom (ie, lower symptom 
burden). The mean change from baseline analyses 
was documented for all subscales, with a 10-point change 
considered to be clinically meaningful.14 15 The time to 
symptom deterioration or improvement was defined as 
the time from randomisation to the first appearance of 
a score ≥10 points worse or better than baseline, respec-
tively, and was assessed for the symptoms of cough, dysp-
noea or pain in the chest using the QLQ-LC13 scale.14 
The time to symptom deterioration or improvement 
was summarised using the Kaplan-Meier methodology, 
without imputation of missing baseline values. Symptom 
deterioration was also examined for patients with and 
without baseline CNS metastases. Multiple exploratory 
analyses were conducted to understand the patient-re-
ported benefit of alectinib’s CNS activity, including the 
relationship between best overall response (complete or 
partial) and emotional functioning and cognitive func-
tioning. In addition, a comparison of baseline ECOG PS 
and PRO scores was done to evaluate differences in these 
subgroups.
Results
Patients
In total, 87 patients were enrolled between 4 September 
2013 and 4 August 2014. The median age of patients was 
54 years (range 29–79), 45% of patients were male, 90% 
had an ECOG PS of 0 or 1, and 84% of patients were 
white. At baseline, 60% (52/87) of patients had measur-
able and/or non-measurable CNS metastases.
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symptoms and HRQol
The completion rate for patients who undertook PRO 
assessments at baseline was 90% (n=79) for both ques-
tionnaires. At the next subsequent assessment (week 6), 
the completion rates were 78% (n=68) for the EORTC 
QLQ-C30 and 72% (n=63) for the EORTC QLQ-LC13.
Changes from baseline values in symptoms, func-
tioning and HRQoL scales are shown in table 1. 
According to the EORTC QLQ-C30, on average, 
patients at the first postbaseline visit (week 6) showed 
improvements in their GHS and all five functioning 
scales compared with baseline, with clinically mean-
ingful mean changes in GHS (mean change±SD: 
15.89±25.66), social functioning (11.20±23.20) and 
role functioning (14.84±32.00) (table 1; figure 1A). At 
week 12, the change from baseline in emotional func-
tioning subscale had reached the clinically meaningful 
threshold at a mean value of 11.01±17.04 (n=54). The 
initial clinically meaningful improvement in GHS from 
the first assessment date was maintained during study 
treatment, as the mean value remained ≥10 points above 
baseline until just before the last study visit (figure 1B). 
Immediate improvements postbaseline were noted 
in all but one of the symptom subscale assessments 
using the EORTC QLQ-C30 (figure 2A). Clinically 
meaningful mean symptom reductions were seen for 
fatigue (10.94±25.70), pain (–12.50±33.47), dyspnoea 
(–12.17±32.96) and appetite loss (−16.67±30.28).
An improvement from baseline was also seen in 
common treatment-related symptoms such as nausea and 
Table 1 Baseline, week 6 and mean change from baseline values for the QLQ-C30 and QLQ-LC13
Baseline mean±SD
Baseline 
median
Week 
6 mean±SD
Week 
6 median
Mean change from 
baseline±SD
Median change 
from baseline
Global health status 
(QLQ-C30)
53.59±24.27 58.33 71.94±20.05 75.00 15.89±25.66 16.67
Functioning (QLQ-C30)
  Physical 69.96±24.43 73.33 76.18±20.19 80.00 4.69±17.44 0.00
  Social 60.55±35.32 66.67 75.98±25.85 83.33 11.20±23.20 0.00
  Role 58.86±34.06 66.67 76.72±27.34 83.33 14.84±32.00 0.00
  Cognitive 77.85±24.13 83.33 81.62±24.63 83.33 2.34±20.76 0.00
  Emotional 73.49±21.40 75.00 81.13±19.03 83.33 7.99±18.75 8.33
Symptoms (QLQ-C30)
  Fatigue 45.57±27.02 44.44 33.33±24.13 33.33 –10.94±25.70 –11.11
  Nausea and vomiting 15.61±20.73 0.00 7.84±17.15 0.00 –6.77±19.63 0.00
  Pain 36.29±33.63 33.33 22.30±26.95 16.67 –12.50±33.47 0.00
  Dyspnoea 33.33±30.86 33.33 22.55±24.73 33.33 –12.17±32.96 0.00
  Insomnia 31.22±30.82 33.33 22.06±25.50 33.33 –9.38±29.38 0.00
  Appetite loss 29.96±33.16 33.33 11.76±23.58 0.00 –16.67±30.28 0.00
  Constipation 20.25±26.38 0.00 27.45±29.89 33.33 9.90±30.68 0.00
  Diarrhoea 13.25±23.01 0.00 4.90±15.52 0.00 –7.41±25.00 0.00
Symptoms (QLQ-LC13)
  Dyspnoea 30.85±27.13 22.22 23.28±21.56 22.22 –8.24±22.57 0.00
  Cough 33.76±27.47 33.33 19.58±21.28 33.33 –13.89±31.47 0.00
  Haemoptysis 1.27±6.41 0.00 0.53±4.20 0.00 –1.11±6.03 0.00
  Sore mouth 5.06±16.09 0.00 2.12±8.19 0.00 –1.11±13.68 0.00
  Dysphagia 4.64±11.61 0.00 1.59±7.16 0.00 –1.67±11.36 0.00
  Peripheral neuropathy 13.08±22.28 0.00 15.87±25.30 0.00 6.11±17.88 0.00
  Alopecia 11.69±25.80 0.00 9.52±22.74 0.00 –1.13±22.29 0.00
  Pain in the chest 21.52±28.6 0.00 5.82±17.50 0.00 –16.67±29.75 0.00
  Pain in the arm or 
shoulder
16.88±28.18 0.00 9.52±19.33 0.00 –7.22±25.37 0.00
  Pain in other parts 44.00±36.42 33.33 25.27±33.43 0.00 –16.96±42.78 0.00
Values in bold represent clinically meaningful changes from baseline (ie, ≥10 point change from baseline).
Data cut-off: 27 April 2015.
QLQ-C30, 30-Item Quality of Life Questionnaire-Core; QLQ-LC13, 13-Item Quality of Life Questionnaire-lung cancer-specific module.
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vomiting, insomnia and diarrhoea. The only treatment-re-
lated symptom to worsen during alectinib treatment was 
constipation (mean change: 9.90±30.68); however, this 
did not reach the clinically meaningful threshold.
Analysis of the EORTC QLQ-LC13 also showed 
mean improvement in all but one of the symptom 
and subscale assessments (figure 2B). By the 
first postbaseline assessment (6 weeks), clinically 
meaningful improvement was seen in patient-re-
ported cough (–13.89±31.47), pain in the chest 
(–16.67±29.75) and pain in other parts (–16.96±42.78) 
(table 1, figure 2B).
Figure 1 (A) Mean change from baseline in global health status and functional scales of the QLQ-C30 after 6 weeks of 
alectinib treatment. (B) Maintenance of clinically meaningful improvement in global health status throughout the study. HRQoL, 
health-related quality of life; QLQ-C30, 30-Item Quality of Life Questionnaire-Core.
Open access
5Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364 Ou S-HI, et al. ESMO Open 2018;3:e000364. doi:10.1136/esmoopen-2018-000364
Clinically meaningful improvement of similar magni-
tude was seen in the mean GHS over time in both patients 
with or without CNS metastases at baseline (figure 3).
Treatment with alectinib resulted in a median time to 
symptom improvement, using the composite endpoint 
of cough, dyspnoea and pain in the chest, of 1.4 months 
(95% CI 1.4 to 1.6; 6.1 weeks (95% CI 6.1 to 7.0 weeks)), 
with more than 50% of patients showing improvement 
within the first few weeks (figure 4A). The median time 
to symptom deterioration, defined as being free of a 
clinically meaningful deterioration in cough, dyspnoea 
or chest pain, was 5.1 months (95% CI 2.8 to 6.8; 22.1 
weeks) using the EORTC QLQ-LC13 (figure 4B).
Relationship between best overall response, emotional 
functioning and cognitive functioning
Online supplementary figure 1 shows the mean changes 
from baseline in patient-reported emotional and 
cognitive functioning for both responders (complete 
or partial response) and non-responders over the 
Figure 2 Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment 
according to (A) the QLQ-C30 and (B) the QLQ-LC13. QLQ-C30, 30-Item Quality of Life Questionnaire-Core; QLQ-LC13, 13-
Item Quality of Life Questionnaire-lung cancer-specific module.
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66-week study period. On average, patients who were 
responders generally maintained or improved their 
level of emotional functioning and cognitive func-
tioning while on treatment through week 66. Patients 
who were non-responders reported either maintained 
or modestly decreased scores for both functioning 
scales while on treatment.
Relationship between eCoG Ps and PRos
An exploratory analysis to show the relationship 
between ECOG PS and baseline PRO scores was under-
taken and, according to the respective items and scales 
of the EORTC QLQ-C30, patients with a higher ECOG 
PS (1 or 2) had worse mean symptom values at base-
line for appetite loss, constipation, fatigue, nausea and 
vomiting, and pain, compared with patients with an 
ECOG PS of 0 (online supplementary table 1), as would 
be expected (patients with an ECOG PS of 0 are by defi-
nition asymptomatic). Similarly, patients with a higher 
ECOG PS had lower mean scores across all five func-
tioning scales. With respect to the items and scales of the 
EORTC QLQ-LC13, a higher ECOG PS was associated 
with worse mean baseline symptom scores in dysphagia, 
alopecia, pain in other parts and sore mouth, compared 
with an ECOG PS of 0 (online supplementary table 1).
dIsCussIon
Alectinib has shown promising efficacy in the treat-
ment of ALK-positive NSCLC, both systemically and 
Figure 3 Mean change from baseline in HRQoL scores for patients with and without baseline CNS metastases. Data cut-off: 
27 April 2015. CNS, central nervous system; HRQoL, health-related quality of life. 
Figure 4 Kaplan-Meier plots of (A) time to first 
improvement and (B) time to first deterioration in pain 
in the chest, cough and dyspnoea, according to the 13-
Item Quality of Life Questionnaire-lung cancer-specific 
module.
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in the CNS,5–9 and is well tolerated. Additionally, 
alectinib has now demonstrated significantly improved 
progression-free survival over crizotinib in patients with 
advanced treatment-naïve ALK+ NSCLC.9 This current 
analysis is the first to demonstrate that alectinib can 
both improve patient-reported symptom burden and 
enhance HRQoL.
By the first postbaseline PRO assessment (week 6), 
patients reported a clinically meaningful improvement 
in many lung cancer symptoms (fatigue, dyspnoea, 
cough, pain, chest pain, pain in other parts), suggesting 
an immediate symptom benefit with treatment. 
Furthermore, time-to-event analyses concerning core 
lung cancer symptoms of dyspnoea, cough and chest 
pain demonstrated a median time to symptom improve-
ment of 1.4 months, which corresponds to the first 
postbaseline PRO assessment. The immediate symptom 
benefit with alectinib was sustained for patients on treat-
ment; additional time-to-event analyses indicated that 
the median time to symptom deterioration was approx-
imately 5.1 months from baseline. Correspondingly, a 
clinically meaningful improvement in GHS was seen 
at the earliest postbaseline PRO assessment and main-
tained until before the last study visit, demonstrating 
an early and sustained improvement in HRQoL for 
alectinib-treated patients in this study. This pattern of 
lung cancer symptom and HRQoL improvement was 
observed in patients irrespective of the presence of CNS 
metastases at baseline. A clinically meaningful improve-
ment in loss of appetite was also seen; a recent study 
by Patel et al16 demonstrated that weight gain, due to 
overall improvement of appetite loss and improvement 
in nausea/vomiting, can be used as an indicator of clin-
ical benefit. This PRO finding was supported via obser-
vations of weight gain in 18.6% of patients in the North 
American study (NP28761; NCT01871805) and in 
12.3% of patients in the phase II global study (NP28673; 
NCT018011) at the updated 2016 data cut-offs; however, 
this gain could also be related to possible increases in 
fluid retention.
The baseline values observed in this study were 
similar to historical values reported in patients with 
stage III/IV lung cancer using the EORTC QLQ-C30 
questionnaire.17 The large SDs observed throughout 
these analyses are common for skewed populations, 
which is a limitation of the mean change score esti-
mates; meaningful median improvements, however, 
were also seen in the GHS and fatigue domains of the 
EORTC QLQ-C30.
In conclusion, patients treated with alectinib in the 
North American NP28761 study reported clinically 
meaningful improvement in key lung cancer symp-
toms, patient-reported function and HRQoL while 
remaining a tolerable treatment option. In the ALUR 
study (NCT02604342), alectinib improved HRQoL, 
functioning and symptom burden versus chemotherapy 
in patients with ALK+ NSCLC after crizotinib failure 
(ALUR, NCT02604342).18 Quality of life endpoints 
are being evaluated in two first-line phase III studies 
investigating alectinib (ALEX, NCT020758409 and 
J-ALEX, JapicCTI-132316).19
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